Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.
Hyun C. Chung, MD, PhD
Advertisement
Articles by Hyun C. Chung, MD, PhD
Hyun C. Chung, MD, PhD, professor at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, Republic of Korea, discusses a joint analysis of the KEYNOTE-028 and KEYNOTE-158 trials in patients with advanced small cell lung cancer (SCLC).
Advertisement
Latest Updated Articles
Dr. Chung on a Joint Analysis of Immunotherapy Trials in SCLCPublished: April 27th 2019 | Updated:
Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric CancerPublished: March 6th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5